New-onset anti-melanoma differentiation-associated gene 5 antibody positive clinically amyopathic dermatomyositis following COVID-19: A case report.

New-onset anti-melanoma differentiation-associated gene 5 antibody positive clinically amyopathic dermatomyositis following COVID-19: A case report.

Publication date: Dec 11, 2025

Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a life-threatening respiratory illness that shares clinical similarities with autoimmune diseases, which some patients subsequently develop. We herein report a case of an older Japanese patient who presented with skin rash, relapsing progressive interstitial lung disease, and anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody seropositivity after COVID-19 infection. Although the patient was elderly, her symptoms improved with the administration of corticosteroids, tacrolimus, and intravenous cyclophosphamide, indicating that this combination may be a viable treatment option for anti-MDA5 antibody-positive pneumonia, which is a complication of COVID-19.

Concepts Keywords
Amyopathic amyopathic dermatomyositis
Cyclophosphamide autoimmune diseases
Japanese coronavirus disease 2019
Pneumonia intravenous cyclophosphamide

Semantics

Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH amyopathic dermatomyositis
disease MESH COVID-19
pathway KEGG Coronavirus disease
disease MESH severe acute respiratory syndrome
disease MESH autoimmune diseases
disease MESH skin rash
disease MESH interstitial lung disease
disease MESH infection
drug DRUGBANK Tacrolimus
drug DRUGBANK Cyclophosphamide
disease MESH pneumonia
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *